TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1

2011 ◽  
Vol 18 (7) ◽  
Author(s):  
S. Petta ◽  
V. Di Marco ◽  
R. Di Stefano ◽  
D. Cabibi ◽  
C. Cammà ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Genotype 1 ◽  
Tyg Index ◽  
Homa Score

scholarly journals Different PEGylated Interferon Ribavirin Therapy in Non-Responders with Chronic Hepatitis C Virus Infection

2012 ◽  
Vol 2 (2) ◽  
pp. 9-13
Author(s):  
Hisham O. Akbar
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Chain Reaction ◽  
Chronic Hepatitis C Virus ◽  
Polymerase Chain

Background: PEGylated interferon and ribavirin therapy is the current standard of care for patients with chronic Hepatitis C virus. It is unknown whether retreatment may be beneficial in non-responders. Methods: Patients who failed to respond to either PEG-Intron or Pegasys with ribavirin were switched to a different PEGylated interferon with ribavirin. Patients were assessed for virologic response by a decrease in viral load levels using a polymerase chain reaction assay. Only patients who had a negative viral load at week 24 were allowed to continue treatment for 48 weeks. Patients with a negative polymerase chain reaction assay after 6 months off treatment were considered as responders to the retreatment regimen. Results: A total of 16 patients were retreated. The combination of Pegasys and ribavirin was administered to 3 patients, and 13 patients received PEG-Intron with ribavirin. Patients had either genotype 1 or 4. Only 4 patients responded to retreatment with PEG-Intron (25%). The responders were female, had a low viral load and had an early significant viral load reduction. Three patients had genotype 4, and one had genotype 1. Conclusion: Retreatment with different PEGylated interferon in patients who failed previous treatment may have a role in the selected patients infected with chronic Hepatitis C virus.

scholarly journals Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients

2009 ◽  
Vol 2009 ◽  
pp. 1-5
Author(s):  
Ioannis S. Elefsiniotis ◽  
Christos Pavlidis ◽  
Elena Vezali ◽  
Theodoros Mariolis-Sapsakos ◽  
Sotirios Koutsounas ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 1 ◽  
Treatment Naïve ◽  
The Impact

Aim. To evaluate the impact of hepatitis B core antibody (anti-HBc) seropositivity in sustained virological response (SVR) rates in treatment-naïve, chronic hepatitis C (CHC) patients with high pretreatment viral load (>800000 IU/mL).Methods. 185 consecutive CHC patients (14.4% cirrhotics, 70.2% prior intravenous drug users) treated with pegylated interferon-a2b plus ribavirin, for 24 or 48 weeks based on viral genotype, were retrospectively analyzed. SVR was confirmed by undetectable serum HCV-RNA six months after the end of treatment schedule.Results. Thirty percent of CHC/HBsAg-negative patients were anti-HBc-positive. Anti-HBc positivity was more prevalent in cirrhotic, compared to noncirrhotic patients (76.9% versus 19.5%,P<.05). Serum HBV-DNA was detected in the minority of anti-HBc-positive patients (1.97%). Overall, 62.1% of patients exhibited SVR, while 28.6% did not; 71.4% of non-SVRs were infected with genotype 1. In the univariate analysis, the anti-HBc positivity was negatively associated with treatment outcome (P=.065). In the multivariate model, only the advanced stage of liver disease (P=.015) and genotype-1 HCV infection (P=.003), but not anti-HBc-status (P=.726), proved to be independent predictors of non-SVR.Conclusion. Serum anti-HBc positivity does not affect the SVR rates in treatment-naïve CHC patients with high pretreatment viral load, receiving the currently approved combination treatment.

Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1

2015 ◽  
Vol 87 (12) ◽  
pp. 2082-2089
Author(s):  
Yoshiaki Iwasaki ◽  
Ryo-ichi Okamoto ◽  
Yasushi Ishii ◽  
Yasuyuki Araki ◽  
Noriaki Hashimoto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Randomized Trial ◽  
Chronic Hepatitis C ◽  
Older Patients ◽  
Low Dose ◽  
High Viral Load ◽  
Genotype 1 ◽  
Peginterferon Α

scholarly journals OPPORTUNITIES AND PROSPECTS FOR INCORPORATING A THIRD DRUG TO THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

2013 ◽  
Vol 18 (5) ◽  
pp. 9-14
Author(s):  
T. V Sologub ◽  
V. V Tsvetkov ◽  
E. G Deeva ◽  
I. I Tokin
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Clinical Symptoms ◽  
Sustained Viral Response ◽  
Control Group ◽  
Genotype 1 ◽  
Viral Response ◽  
Hcv Genotype 1

In order to evaluate the efficiency and safety of using the drug Ingaron in treatment ofpatients with chronic hepatitis C (CHC) an open, randomized, control comparative study has been performed. We examined of 132 CHC patients aged from 18 to 58 years. All patients were selected into 3 groups depending on the type of therapy. The following drugs: Ribavirin, Alfarona, Ingaron were included in regimens of therapy. The course of the disease in examined CHC patients was characterized by mild clinical symptoms, the presence of the expressed cytolytic syndrome more than in half of the patients (50.8%), high levels of «viral load» in 61.6% of patients with the establishment of a direct correlation between high ALT and viremia levels (r=+0,67). The average level of «viral load» in patients infected with no-1 genotype of hepatitis C, at the start of therapy was 1,4 times higher than in those with genotype 1, amounting to 1,8 x 106 and 1,3 x 106 IU/ml, respectively. Patients infected with HCV genotype 1 and receiving therapy with Ingaron for 24 and 12 weeks, achieved sustained viral response in 65,0% and 80,0% of cases whereas patients infected with «no 1» genotype - in 73,9%, and 84,6% of cases, respectively. At the same time, in patients from the control group the sustained viral response was observed only in 56,0% and 60,0% of cases (1 and «no 1» genotypes, respectively). The inclusion of Ingaron into the classical medical regimen was accompanied by a reduction in the incidence of adverse reactions during treatment.

Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection

2009 ◽  
Vol 104 (3) ◽  
pp. 598-604
Author(s):  
Ching-Sheng Hsu ◽  
Chen-Hua Liu ◽  
Chun-Jen Liu ◽  
Chia-Chi Wang ◽  
Chi-Ling Chen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Lipid Profiles ◽  
Genotype 1 ◽  
Chronic Hepatitis C Patients

scholarly journals Association of Visceral Obesity with High Viral Load and Histological Findings in Elderly Patients with Genotype 1 Chronic Hepatitis C

2013 ◽  
Vol 52 (15) ◽  
pp. 1665-1673 ◽  
Author(s):  
Hironori Tsuzura ◽  
Takuya Genda ◽  
Shunsuke Sato ◽  
Katsuharu Hirano ◽  
Yoshio Kanemitsu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Elderly Patients ◽  
Chronic Hepatitis C ◽  
Visceral Obesity ◽  
High Viral Load ◽  
Genotype 1 ◽  
Histological Findings

scholarly journals Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1

Hepatology ◽  
2010 ◽  
Vol 52 (5) ◽  
pp. 1543-1552 ◽  
Author(s):  
Salvatore Petta ◽  
Marco Amato ◽  
Daniela Cabibi ◽  
Calogero Cammà ◽  
Vito Di Marco ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
High Viral Load ◽  
Visceral Adiposity ◽  
Visceral Adiposity Index ◽  
Genotype 1 ◽  
Histological Findings ◽  
Adiposity Index

scholarly journals Different PEGylated Interferon Ribavirin Therapy in Non-Responders with Chronic Hepatitis C Virus Infection

2012 ◽  
Vol 2 (2) ◽  
pp. 9-13
Author(s):  
Hisham O. Akbar
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Chain Reaction ◽  
Chronic Hepatitis C Virus ◽  
Polymerase Chain

Background: PEGylated interferon and ribavirin therapy is the current standard of care for patients with chronic Hepatitis C virus. It is unknown whether retreatment may be beneficial in non-responders. Methods: Patients who failed to respond to either PEG-Intron or Pegasys with ribavirin were switched to a different PEGylated interferon with ribavirin. Patients were assessed for virologic response by a decrease in viral load levels using a polymerase chain reaction assay. Only patients who had a negative viral load at week 24 were allowed to continue treatment for 48 weeks. Patients with a negative polymerase chain reaction assay after 6 months off treatment were considered as responders to the retreatment regimen. Results: A total of 16 patients were retreated. The combination of Pegasys and ribavirin was administered to 3 patients, and 13 patients received PEG-Intron with ribavirin. Patients had either genotype 1 or 4. Only 4 patients responded to retreatment with PEG-Intron (25%). The responders were female, had a low viral load and had an early significant viral load reduction. Three patients had genotype 4, and one had genotype 1. Conclusion: Retreatment with different PEGylated interferon in patients who failed previous treatment may have a role in the selected patients infected with chronic Hepatitis C virus.

Sign in / Sign up

Export Citation Format

Share Document